IGKV1OR22-5

Across TCGA pan-cancer cohorts, IGKV1OR22-5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGKV1OR22-5 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IGKV1OR22-5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGKV1OR22-5 expression acts as an unfavorable survival marker.

HNSC, LUSC, and SKCM are the cancer types where IGKV1OR22-5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.087	0.768	<.001	48	view →
LUSC	OS	Median	All	0.165	0.675	.019	12	view →
SKCM	OS	Median	III,IV	0.202	0.705	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IGKV1OR22-5–HNSC (OS)

Open the HNSC breakdown →